India’s pharmaceutical pricing authority has implemented a significant 50% increase in price limits for two essential cancer medications following severe shortages triggered by escalating raw material expenses, according to government documentation reviewed by Reuters.
The National Pharmaceutical Pricing Authority utilized emergency provisions to implement the rate adjustments after securing federal government authorization based on public interest considerations, as outlined in documentation dated June 11.
Healthcare facilities across the world’s most populous nation have been struggling with insufficient supplies of platinum-containing cancer medications cisplatin and carboplatin, with government-operated medical centers particularly affected by the shortages.
These medications, which are essential for treating ovarian, lung and bladder cancers, operate under government-imposed pricing restrictions and oversight.
The maximum allowable price for cisplatin increased from 7.26 rupees to 10.89 rupees ($0.1144) per milliliter, while carboplatin pricing rose from 60.49 rupees to 90.74 rupees ($0.9530) per milliliter, excluding applicable taxes, the documentation revealed.
“The authority noted concerns regarding shortage and supply disruptions of carboplatin and cisplatin formulations, which are essential oncology medicines used in the treatment of various cancers,” the NPPA stated, emphasizing that consistent availability of these medications is vital for public health.
Multiple pharmaceutical companies produce these medications, including Cipla, Intas Pharmaceuticals and specialized oncology manufacturers such as Naprod Life Sciences and Venus Remedies.
The pricing adjustment represents a temporary measure that will undergo evaluation after six months, according to the NPPA. India relies significantly on platinum imports for use across multiple industries including automotive, jewelry, chemical and pharmaceutical sectors.
Deliveries of the precious metal from major producing nations like South Africa have decreased due to increasing costs, while Middle East conflicts have created additional supply chain complications and elevated production expenses, according to medical professionals and industry leaders who spoke with Reuters.
The enhanced price limits provide assistance to pharmaceutical manufacturers who had temporarily suspended production as platinum costs more than doubled due to limited availability, high demand and reduced stockpiles.
